Abstract: One disadvantage of adeno-associated virus (AAV) is low gene expression efficiency due to delayed expression of the inserted gene. Provided is a vector plasmid for producing a vector genome to be inserted into an adeno-associated virus (AAV). The vector plasmid is provided with a vector genome cassette as a template of the vector genome, and the vector genome cassette is provided with: (1) an expression cassette including a nucleic acid molecule encoding a target gene and (b) a nucleic acid molecule encoding an expression regulatory region that allows expression of the target gene; and (2) two nucleic acid molecules positioned on both sides of the expression cassette and encoding inverted terminal repeats (ITRs). Also provided is a pharmaceutical composition containing the AVV vector, for treating or preventing an eye disease or disease associated with same.

Abstract: A suppression of postsurgical recurrence and/or metastasis of cancer by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery is disclosed. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, containing a beta-blocker and being administered during a perioperative period of cancer surgery.

Abstract: A method of detecting somatic mutations of tumor marker genes includes recovering a peripheral blood mononuclear cell layer from a blood sample collected from a subject and examining whether or not a nucleic acid derived from tumor marker genes having somatic mutations is detected from DNA included in the peripheral blood mononuclear cell layer.

Abstract: The present invention aims to develop a method capable of evaluating T cell immune function. A method for evaluating T cell immune function including detecting and quantifying soluble PD-L1 having a binding ability to PD-1, and an ELISA system used for detecting and quantifying bsPD-L1, including a carrier with a solid-phased PD-1 protein, a means for reacting the carrier and a test sample, and a means for detecting and quantifying soluble PD-L1 bound to the carrier as bsPD-L1.

Abstract: It is an object of the preset invention to provide a usefultool for treating or preventing infections disease. According to the present invention, provided is a therapeutic or preventive agent for infections disease, comprising, as an active ingridient, a fusion protein of (a) at least one polypeptide comprising an amino acid sequence that is identical to or substantially identical to the amino acid sequence of the N-terminal domain of pertraxin 3 capable of binding to a bistone to form a polypeptide aggregate and (b) the Fe portion of an immunoglobulin, or a pharmacologically acceptable salt thereof.

Abstract: An automatic needle mover for moving a medical threaded needle includes: two shafts extending in the same direction and slidable relative to each other along a longitudinal direction; a needle-holding portion provided on one end side of the second shaft; a needle-receiving portion provided on one end side of the first shaft; and a handle serving as a control portion for controlling the sliding of the two shafts. The needle-holding portion has a first claw portion protruding in a direction intersecting the longitudinal direction of the shafts. The needle-receiving portion has a second claw portion protruding in a direction intersecting the longitudinal direction of the shafts. As a result of the sliding of the two shafts, the needle-holding portion and the needle-receiving portion become close to each other and a straight needle held by the needle-holding portion can be press-fitted into the needle-receiving portion.

Abstract: A method for producing a nucleic acid-encapsulated adeno-associated virus (AAV) hollow particle, comprising the following steps: (1) preparing a linear nucleic acid fragment comprising a sequence for A region and a sequence for D? region in an AAV inverted terminal repeat (ITR) (i.e., an AD sequence) or a sequence complementary to the AD sequence and a target gene sequence; (2) introducing the nucleic acid fragment prepared in step (1) into a cell capable of producing an AAV hollow particle; and (3) culturing the cell obtained in step (2).

Abstract: Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex.

Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

Abstract: An automatic needle mover (1) for moving a medical threaded needle includes: two shafts (a first shaft (11) and a second shaft (12)) extending in the same direction and slidable relative to each other along a longitudinal direction; a needle holding portion (a second needle support portion (22)) provided on one end side of the second shaft (12); a needle-receiving portion (a first needle support portion (21)) provided on one end side of the first shaft (11); and a handle (30) serving as a control portion for controlling the sliding of the two shafts. The needle holding portion has a first groove portion provided in a first claw portion protruding in a direction intersecting the longitudinal direction of the shafts. The needle-receiving portion has a second groove portion provided in a second claw portion protruding in a direction intersecting the longitudinal direction of the shafts.

Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

Abstract: An object of the present invention is to provide a vector capable of oligodendrocyte-specifically suppressing expression of the PLP1 gene for treating PMD caused by abnormality of the PLP1 gene, and a promoter and miRNA therefor, and a pharmaceutical composition comprising the vector. The oligodendrocyte-specific promoter of the present invention comprises a nucleic acid having a sequence identity of at least 90% to a nucleotide sequence set forth in SEQ ID NO: 1. The miRNA of the present invention specific to the PLP1 gene comprises a pair of nucleotide sequences consisting of a specific antisense sequence and sense sequence.

Abstract: The present invention aims to develop a method capable of evaluating T cell immune function. A method for evaluating T cell immune function including detecting and quantifying soluble PD-L1 having a binding ability to PD-1, and an ELISA system used for detecting and quantifying bsPD-L1, including a carrier with a solid-phased PD-1 protein, a means for reacting the carrier and a test sample, and a means for detecting and m quantifying soluble PD-L1 bound to the carrier as bsPD-L1.

Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

Abstract: A method of detecting somatic mutations of tumor marker genes includes recovering a peripheral blood mononuclear cell layer from a blood sample collected from a subject and examining whether or not a nucleic acid derived from tumor marker genes having somatic mutations is detected from DNA included in the peripheral blood mononuclear cell layer.

Abstract: The inventors found that postsurgical recurrence and/or metastasis of cancer is suppressed by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, comprising a beta-blocker and being administered during a perioperative period of cancer surgery.

Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.

Abstract: A method for evaluating a health condition, includes: measuring a test amount of cell free DNA per unit amount of a body fluid sample collected from a subject after tumor resection; and comparing the measured test amount of cell free DNA with a reference value so as to evaluate a health condition of the subject. The reference value is one of a predetermined threshold value; an amount of cell free DNA per unit amount of a body fluid sample collected from the subject before tumor resection; an amount of cell free DNA per unit amount of a body fluid sample collected from the subject between 1 week and 3 months after tumor resection; and an amount of cell free DNA per unit amount of a body fluid sample collected from the subject by the time of collecting the body fluid sample for measuring the test amount of cell free DNA.

Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.